Endobronchial valve treatment triples peri-procedural mortality odds in severe emphysemaEndobronchial Valve Treatment Shows Mixed Results for Emphysema Mortality
Expert review of medical devicesPublished September 2, 2026Study authors: Mari Pier-Valerio, Ielo Simone, Coppola Angelo, Ricci Alberto, Licata Maria Angela, Lipsi Roberto, D…PubMed ↗DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider EBV's increased peri-procedural mortality risk when counseling severe emphysema patients.
This meta-analysis pooled data from 819 patients with severe emphysema to evaluate the impact of endobronchial valve (EBV) treatment versus standard of care on mortality outcomes. The primary outcome was overall mortality, with secondary outcomes including peri-procedural mortality (≤90 days) and post-procedural mortality (>90 days).
The analysis found that peri-procedural mortality was significantly higher with EBV treatment (Peto OR 3.70, 95% CI 1.07-12.84; p=0.03). In contrast, post-procedural mortality beyond 90 days was not significantly increased (Peto OR 0.50, 95% CI 0.12-2.09; p=0.33), and overall mortality did not differ significantly between groups (Peto OR 1.57, 95% CI 0.61-4.04; p=0.35). The authors note that the mortality signal associated with EBV is specifically linked to the peri-procedural period, with pneumothorax-related deaths identified as a driver.
Limitations were not reported in the source, and the certainty of evidence was not graded. The analysis did not report absolute mortality rates, follow-up duration, or details on adverse events beyond pneumothorax-related deaths.
These findings may inform patient counseling, peri-procedural management, and the design of future trials with survival endpoints. Clinicians should weigh the increased short-term mortality risk against potential long-term benefits, though the lack of significant overall mortality difference suggests careful patient selection is essential.
How this fits prior evidence
This meta-analysis adds a mortality-focused perspective to prior coverage on severe emphysema interventions. It extends earlier findings on lung volume reduction surgery (LVRS), which reported a 7.3% mortality estimate with significant FEV1 improvement, by highlighting that EBV also carries a peri-procedural mortality risk. The increased peri-procedural mortality (Peto OR 3.70) contrasts with the lack of significant overall mortality difference, echoing the caution that such procedures are not low risk. It also complements prior notes on postoperative air leaks with non-powered staplers in LVRS, underscoring the importance of procedural safety in this population.
A meta-analysis of 819 patients with severe emphysema looked at the impact of endobronchial valve (EBV) treatment on survival rates. The study compared patients receiving these valves to those receiving the standard of care. The goal was to see if the procedure changed the overall risk of death for those with the condition.
The results showed that the total number of deaths did not differ significantly between the two groups over the long term. However, there was a notable difference in the early stages of treatment. Patients who received endobronchial valves had a significantly higher risk of death within the first 90 days after the procedure. This early risk was linked to complications like pneumothorax.
Because the increased risk is concentrated in the period immediately following the procedure, these findings are important for doctors when they talk to patients. It highlights the need for careful management during the first few months of treatment. You should talk to your doctor to understand how these risks apply to your specific health situation.
What this means for you:
Endobronchial valves do not change overall mortality but are linked to higher risk in the first 90 days.
Common questions
Is it safe to get endobronchial valves for emphysema?
The study found that the procedure did not significantly change overall mortality for patients with severe emphysema. However, there was a significantly higher risk of death within the first 90 days following the procedure. This early risk was specifically linked to complications like pneumothorax. You should discuss these specific risks with your doctor.
What happens after the procedure is finished?
The study found that mortality after 90 days did not show a significant increase for those receiving endobronchial valves. The higher risk was concentrated in the peri-procedural period, which is the time immediately following the treatment. This means the risk profile changes as the patient moves past the initial recovery phase.
How many people were included in this study?
The meta-analysis included data from 819 patients who had severe emphysema. This large group allowed researchers to compare the outcomes of endobronchial valve treatment against the standard of care to determine the impact on survival rates.
INTRODUCTION: Endobronchial valve (EBV) treatment improves functional outcomes in severe emphysema, but its effect on mortality remains uncertain. Recent evidence suggested increased mid-term mortality with EBV, without distinguishing early peri-procedural deaths from later post-procedural mortality.
METHODS: PubMed, Embase, Cochrane CENTRAL, and Web of Science were systematically searched from database inception through March 2026 for randomized controlled trials comparing EBV with standard of care (SoC) in patients with severe emphysema. The main outcome was overall mortality, further stratified into peri-procedural mortality (≤90 days) and post-procedural mortality (>90 days).
RESULTS: Six randomized controlled trials involving 819 patients (515 EBV, 304 SoC) were included. Peri-procedural mortality was significantly higher with EBV (Peto OR 3.70, 95% CI 1.07-12.84; = 0.03). Post-procedural mortality was not significantly increased (Peto OR 0.50, 95% CI 0.12-2.09; = 0.33). Overall mortality did not differ significantly between groups (Peto OR 1.57, 95% CI 0.61-4.04; = 0.35).
CONCLUSIONS: In randomized trials, the mortality signal associated with EBV appears confined to the peri-procedural period and is largely driven by pneumothorax-related deaths. No excess mortality was observed beyond 90 days. These findings may inform patient counseling, peri-procedural management, and future trials with survival endpoints.
